- Home
- Publications
- Publication Search
- Publication Details
Title
Brentuximab vedotin
Authors
Keywords
-
Journal
mAbs
Volume 4, Issue 4, Pages 458-465
Publisher
Informa UK Limited
Online
2012-06-29
DOI
10.4161/mabs.20230
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Novel Role of CD30L/CD30 Signaling by T-T Cell Interaction in Th1 Response against Mycobacterial Infection
- (2014) C. Tang et al. JOURNAL OF IMMUNOLOGY
- Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009
- (2011) J. Sjoberg et al. BLOOD
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
- (2011) T. A. Fehniger et al. BLOOD
- EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
- (2011) W. Kempf et al. BLOOD
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
- (2011) R. L. Piekarz et al. BLOOD
- A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
- (2011) A. M. Evens et al. BLOOD
- Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)
- (2011) Claire E. Dearden et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- OX40 and CD30 signals in CD4+ T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T-cell memory but not effector function
- (2011) David R. Withers et al. IMMUNOLOGICAL REVIEWS
- Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice
- (2011) Fabrina M.Gaspal et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma
- (2011) Kelley V. Foyil et al. LEUKEMIA & LYMPHOMA
- Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
- (2011) O. Merkel et al. MOLECULAR CANCER THERAPEUTICS
- Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma
- (2011) K. A. Blum Hematology-American Society of Hematology Education Program
- Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc RIIIa-158 V/F polymorphism
- (2010) K. A. Blum et al. ANNALS OF ONCOLOGY
- Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
- (2010) Francesco D’Amore et al. BRITISH JOURNAL OF HAEMATOLOGY
- The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
- (2010) Daniela Buglio et al. BRITISH JOURNAL OF HAEMATOLOGY
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma
- (2009) P. M. Cardarelli et al. CLINICAL CANCER RESEARCH
- A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
- (2009) M. Duvic et al. CLINICAL CANCER RESEARCH
- Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies
- (2009) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project
- (2008) K. J. Savage et al. BLOOD
- Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
- (2008) Ezogelin Oflazoglu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients
- (2007) H. Brenner et al. BLOOD
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started